Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentosan polysulfate sodium for bone marrow oedema lesion after acute traumatic knee injury
ACTRN12616000009415Phase 2Terminated
- Sponsor
- Paradigm Biopharmaceuticals
- Start
- Feb 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentosan polysulfate sodium in bone marrow edema syndrome (BMES) and anterior cruciate ligament injury, sponsored by Paradigm Biopharmaceuticals. Primary endpoint: Safety and tolerability. Started Feb 2016; status: terminated.
02
Drugs
pentosan polysulfate sodium
03
Conditions
bone marrow edema syndrome (BMES)anterior cruciate ligament injury
Beyond the preview
Go deeper on ACTRN12616000009415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000009415.